Skip to main content
Valneva SE logo

Valneva SE — Investor Relations & Filings

Ticker · VLA ISIN · FR0004056851 LEI · 969500DIVIP5VKNW4948 PA Manufacturing
Open in API
Filings indexed 1,661 across all filing types
Latest filing 2025-07-11 Regulatory Filings
Country FR France
Listing PA VLA

About Valneva SE

https://valneva.com/

Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet medical needs. The company has leveraged its expertise to commercialize three vaccines, including a single-shot vaccine for chikungunya. Its research and development pipeline features a broad range of vaccine candidates, including those targeting Lyme disease, Shigella, and Zika.

Recent filings

Filing Released Lang Actions
Valneva Announces Lifting of European Medicines Agency’s Temporary Restriction on Use of Chikungunya Vaccine IXCHIQ® in Elderly
Regulatory Filings Classification · 100% confidence The document is a press release dated July 11, 2025, announcing a regulatory decision by the European Medicines Agency (EMA) regarding Valneva's vaccine, IXCHIQ®. It details the lifting of a temporary restriction and provides context on the vaccine's efficacy and safety review. This type of announcement, which communicates a significant business or regulatory event via a press release format, most closely aligns with an Earnings Release (ER) if it were reporting financial results, or a general Regulatory Filing (RNS) if it were a miscellaneous announcement. Since it is a specific, time-sensitive announcement about a product/regulatory status update rather than a comprehensive financial report (like 10-K or IR) or a management discussion (MDA), and it is not a transcript (CT) or a formal proxy/dividend notice, the most appropriate classification is the general regulatory announcement category, RNS, as it is a public disclosure of a material event. However, given the content is a direct announcement of a major operational/regulatory event, and it is not a short notice pointing to an attached report (ruling 2), it functions as an 'Earnings Release' style announcement, even though it's not strictly financial earnings. Comparing the options, 'ER' (Earnings Release) is often used broadly for major period-end announcements, but this is a specific regulatory update. 'RNS' (Regulatory Filings) is the best fit for non-standard, material regulatory news that doesn't fit other specific categories like DIRS, DIV, or CAP. Given the nature of the announcement (EMA decision), RNS is the most accurate fallback for a significant, non-financial regulatory update.
2025-07-11 English
VALNEVA Déclaration d’actions et de droits de vote : 30 juin 2025
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document is a formal declaration of the total number of shares and voting rights for Valneva as of June 30, 2025. It provides specific data on share capital and voting rights, which is a standard regulatory requirement for listed companies in France (AMF regulations). This type of filing is a periodic disclosure of capital structure and voting rights, which falls under the category of Regulatory Filings (RNS) as it does not represent a specific share issuance, director dealing, or dividend announcement, but rather a general regulatory disclosure of share status.
2025-07-03 French
VALNEVA Declaration of shares and voting rights: June 30, 2025
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document is a formal declaration of the total number of shares and voting rights for Valneva as of June 30, 2025. It explicitly lists the share capital, theoretical voting rights, and exercisable voting rights, referencing AMF General Regulations. This type of disclosure is a standard regulatory requirement for companies listed on Euronext Paris to inform the market of changes in share capital and voting rights, which falls under the category of general regulatory announcements.
2025-07-03 English
6-K
Regulatory Filings
2025-06-26 English
Valneva annonce un accord exclusif avec CSL Seqirus pour le marketing et la distribution de ses vaccins en Allemagne
Regulatory Filings Classification · 95% confidence The document is a press release issued by Valneva SE announcing a new exclusive marketing and distribution agreement with CSL Seqirus for its vaccines in Germany. It details the terms of the partnership, the products involved, and the strategic rationale. While it mentions financial figures (Q1 2025 sales), it is not a formal financial report, but rather a corporate announcement regarding business operations and commercial strategy. As it does not fit into specific categories like M&A (which usually refers to corporate mergers/acquisitions of entities) or specific regulatory filings, it falls under the general regulatory announcement category.
2025-06-26 French
Valneva Announces Exclusive Vaccine Marketing and Distribution Agreement for Germany with CSL Seqirus
Regulatory Filings Classification · 95% confidence The document is a press release issued by Valneva SE announcing an exclusive marketing and distribution agreement with CSL Seqirus for its vaccines in Germany. It details the terms of the partnership, the products involved, and provides a brief update on commercial performance. As this is a general corporate announcement regarding a business partnership and does not fit into specific categories like M&A (which usually involves mergers or takeovers) or financial reports, it is classified as a general regulatory filing/announcement.
2025-06-26 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.